Defensive Burying Test

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 123 Experts worldwide ranked by ideXlab platform

Michael Messaoudi - One of the best experts on this subject based on the ideXlab platform.

  • assessment of psychotropic like properties of a probiotic formulation lactobacillus helveticus r0052 and bifidobacterium longum r0175 in rats and human subjects
    British Journal of Nutrition, 2011
    Co-Authors: Michael Messaoudi, Nicolas Violle, Didier Desor, Amine Nejdi, Robert Lalonde, Herve Javelot, Jeanfrancois Bisson, Catherine Rougeot, Matthieu Pichelin, Murielle Cazaubiel
    Abstract:

    In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastroinTestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently Tested in the conditioned Defensive Burying Test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats ( P P P P P P P P P L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers.

  • Assessment of psychotropiclike properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects
    2011
    Co-Authors: Michael Messaoudi, Nicolas Violle, Didier Desor, Amine Nejdi, Robert Lalonde, Herve Javelot, Jeanfrancois Bisson, Catherine Rougeot, Matthieu Pichelin, Murielle Cazaubiel
    Abstract:

    Abstract In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastroinTestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently Tested in the conditioned Defensive Burying Test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats (P,0·05) and alleviated psychological distress in volunteers, as measured particularly by the HSCL-90 scale (global severity index, P, 0·05; somatisation, P, 0·05; depression, P, 0·05; and anger-hostility, P,0·05), the HADS (HADS global score, P, 0·05; and HADSanxiety, P,0·06), and by the CCL (problem solving, P, 0·05) and the UFC level (P,0·05). L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers

  • Anxiolytic-like effects and safety profile of a tryptic hydrolysate from bovine alpha s1-casein in rats
    Fundamental and Clinical Pharmacology, 2009
    Co-Authors: Michael Messaoudi, Henri Schroeder, Robert Lalonde, Didier Desor
    Abstract:

    The anxiolytic activity and adverse benzodiazepine-like effects of a bovine alpha s1-casein tryptic hydrolysate (CH) were evaluated. The effects of CH orally administered at doses of 5 and 15 mg/kg were compared with those of diazepam (DZ) at 3 mg/kg in the conditioned Defensive Burying Test. Rats treated either with CH at 15 mg/kg or with DZ showed a decrease in anxiety. A drug-related difference was observed in terms of duration, as the anxiolytic-like action of CH was maintained after 7 days with twice-daily administration, whereas that of DZ was not. CH and DZ were then evaluated for their potential effects on memory in a passive avoidance paradigm. CH-treated rats had significantly longer latencies before entering the dark compartment where they were previously delivered a shock, indicating better retention relative to DZ-treated rats. In the final Test, CH and DZ were evaluated for place preference, an index of the possible addictive potential of these substances. DZ-treated rats spent more time in the compartment associated with drug exposure than control rats. This effect was not found in CH-treated rats. Thus, CH did not display side effects associated with DZ, despite its affinity for gamma-aminobutyric acid(A) (GABAA) receptors. Specific linking of CH on GABAA receptor function involved in anxiolysis, but not on that implied in memory-impairing effects, may be hypothesized to explain its specific activity. This profile might render it advantageous for nutritional purposes.

  • ethological comparison of the effects of a bovine αs1 casein tryptic hydrolysate and diazepam on the behaviour of rats in two models of anxiety
    Pharmacology Biochemistry and Behavior, 2006
    Co-Authors: Nicolas Violle, Michael Messaoudi, Catherine Lefrancmillot, Didier Desor, Amine Nejdi, Benoit Demagny, Henri Schroeder
    Abstract:

    A bovine αS1-casein tryptic hydrolysate was previously demonstrated to display an anxiolytic-like activity in the conditioned Defensive Burying and in the elevated plus-maze models when i.p. injected. The present study assessed the anxiolytic-like effects of this tryptic hydrolysate after an oral administration in rats faced to the same behavioural situations using diazepam as a reference. In a first experiment, the behavioural effects of the hydrolysate in the conditioned Defensive Burying Test were investigated at doses ranging 5–50 mg/kg. The results showed that the minimal dose required to elicit an anxiolytic-like activity is 15 mg/kg. In a second experiment, the αS1-casein tryptic hydrolysate (15 mg/kg, p.o.) was demonstrated to display an anxiolytic-like activity similar to diazepam (3 mg/kg, p.o.) in the conditioned Defensive Burying Test and the elevated plus-maze. However, the ethological analysis of behaviour indicated that this hydrolysate has a different activity compared to diazepam. While diazepam induced a disinhibition state in rats, possibly related to the risk-taking behaviour observed after a benzodiazepine ingestion in humans, the tryptic hydrolysate did not display such a side effect. These results suggest that the mechanism of action of the bovine αs1-casein tryptic hydrolysate may differ from that of diazepam.

Didier Desor - One of the best experts on this subject based on the ideXlab platform.

  • assessment of psychotropic like properties of a probiotic formulation lactobacillus helveticus r0052 and bifidobacterium longum r0175 in rats and human subjects
    British Journal of Nutrition, 2011
    Co-Authors: Michael Messaoudi, Nicolas Violle, Didier Desor, Amine Nejdi, Robert Lalonde, Herve Javelot, Jeanfrancois Bisson, Catherine Rougeot, Matthieu Pichelin, Murielle Cazaubiel
    Abstract:

    In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastroinTestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently Tested in the conditioned Defensive Burying Test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats ( P P P P P P P P P L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers.

  • Assessment of psychotropiclike properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects
    2011
    Co-Authors: Michael Messaoudi, Nicolas Violle, Didier Desor, Amine Nejdi, Robert Lalonde, Herve Javelot, Jeanfrancois Bisson, Catherine Rougeot, Matthieu Pichelin, Murielle Cazaubiel
    Abstract:

    Abstract In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastroinTestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently Tested in the conditioned Defensive Burying Test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats (P,0·05) and alleviated psychological distress in volunteers, as measured particularly by the HSCL-90 scale (global severity index, P, 0·05; somatisation, P, 0·05; depression, P, 0·05; and anger-hostility, P,0·05), the HADS (HADS global score, P, 0·05; and HADSanxiety, P,0·06), and by the CCL (problem solving, P, 0·05) and the UFC level (P,0·05). L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers

  • Anxiolytic-like effects and safety profile of a tryptic hydrolysate from bovine alpha s1-casein in rats
    Fundamental and Clinical Pharmacology, 2009
    Co-Authors: Michael Messaoudi, Henri Schroeder, Robert Lalonde, Didier Desor
    Abstract:

    The anxiolytic activity and adverse benzodiazepine-like effects of a bovine alpha s1-casein tryptic hydrolysate (CH) were evaluated. The effects of CH orally administered at doses of 5 and 15 mg/kg were compared with those of diazepam (DZ) at 3 mg/kg in the conditioned Defensive Burying Test. Rats treated either with CH at 15 mg/kg or with DZ showed a decrease in anxiety. A drug-related difference was observed in terms of duration, as the anxiolytic-like action of CH was maintained after 7 days with twice-daily administration, whereas that of DZ was not. CH and DZ were then evaluated for their potential effects on memory in a passive avoidance paradigm. CH-treated rats had significantly longer latencies before entering the dark compartment where they were previously delivered a shock, indicating better retention relative to DZ-treated rats. In the final Test, CH and DZ were evaluated for place preference, an index of the possible addictive potential of these substances. DZ-treated rats spent more time in the compartment associated with drug exposure than control rats. This effect was not found in CH-treated rats. Thus, CH did not display side effects associated with DZ, despite its affinity for gamma-aminobutyric acid(A) (GABAA) receptors. Specific linking of CH on GABAA receptor function involved in anxiolysis, but not on that implied in memory-impairing effects, may be hypothesized to explain its specific activity. This profile might render it advantageous for nutritional purposes.

  • ethological comparison of the effects of a bovine αs1 casein tryptic hydrolysate and diazepam on the behaviour of rats in two models of anxiety
    Pharmacology Biochemistry and Behavior, 2006
    Co-Authors: Nicolas Violle, Michael Messaoudi, Catherine Lefrancmillot, Didier Desor, Amine Nejdi, Benoit Demagny, Henri Schroeder
    Abstract:

    A bovine αS1-casein tryptic hydrolysate was previously demonstrated to display an anxiolytic-like activity in the conditioned Defensive Burying and in the elevated plus-maze models when i.p. injected. The present study assessed the anxiolytic-like effects of this tryptic hydrolysate after an oral administration in rats faced to the same behavioural situations using diazepam as a reference. In a first experiment, the behavioural effects of the hydrolysate in the conditioned Defensive Burying Test were investigated at doses ranging 5–50 mg/kg. The results showed that the minimal dose required to elicit an anxiolytic-like activity is 15 mg/kg. In a second experiment, the αS1-casein tryptic hydrolysate (15 mg/kg, p.o.) was demonstrated to display an anxiolytic-like activity similar to diazepam (3 mg/kg, p.o.) in the conditioned Defensive Burying Test and the elevated plus-maze. However, the ethological analysis of behaviour indicated that this hydrolysate has a different activity compared to diazepam. While diazepam induced a disinhibition state in rats, possibly related to the risk-taking behaviour observed after a benzodiazepine ingestion in humans, the tryptic hydrolysate did not display such a side effect. These results suggest that the mechanism of action of the bovine αs1-casein tryptic hydrolysate may differ from that of diazepam.

Murielle Cazaubiel - One of the best experts on this subject based on the ideXlab platform.

  • assessment of psychotropic like properties of a probiotic formulation lactobacillus helveticus r0052 and bifidobacterium longum r0175 in rats and human subjects
    British Journal of Nutrition, 2011
    Co-Authors: Michael Messaoudi, Nicolas Violle, Didier Desor, Amine Nejdi, Robert Lalonde, Herve Javelot, Jeanfrancois Bisson, Catherine Rougeot, Matthieu Pichelin, Murielle Cazaubiel
    Abstract:

    In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastroinTestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently Tested in the conditioned Defensive Burying Test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats ( P P P P P P P P P L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers.

  • Assessment of psychotropiclike properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects
    2011
    Co-Authors: Michael Messaoudi, Nicolas Violle, Didier Desor, Amine Nejdi, Robert Lalonde, Herve Javelot, Jeanfrancois Bisson, Catherine Rougeot, Matthieu Pichelin, Murielle Cazaubiel
    Abstract:

    Abstract In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastroinTestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently Tested in the conditioned Defensive Burying Test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats (P,0·05) and alleviated psychological distress in volunteers, as measured particularly by the HSCL-90 scale (global severity index, P, 0·05; somatisation, P, 0·05; depression, P, 0·05; and anger-hostility, P,0·05), the HADS (HADS global score, P, 0·05; and HADSanxiety, P,0·06), and by the CCL (problem solving, P, 0·05) and the UFC level (P,0·05). L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers

Robert Lalonde - One of the best experts on this subject based on the ideXlab platform.

  • assessment of psychotropic like properties of a probiotic formulation lactobacillus helveticus r0052 and bifidobacterium longum r0175 in rats and human subjects
    British Journal of Nutrition, 2011
    Co-Authors: Michael Messaoudi, Nicolas Violle, Didier Desor, Amine Nejdi, Robert Lalonde, Herve Javelot, Jeanfrancois Bisson, Catherine Rougeot, Matthieu Pichelin, Murielle Cazaubiel
    Abstract:

    In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastroinTestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently Tested in the conditioned Defensive Burying Test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats ( P P P P P P P P P L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers.

  • Assessment of psychotropiclike properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects
    2011
    Co-Authors: Michael Messaoudi, Nicolas Violle, Didier Desor, Amine Nejdi, Robert Lalonde, Herve Javelot, Jeanfrancois Bisson, Catherine Rougeot, Matthieu Pichelin, Murielle Cazaubiel
    Abstract:

    Abstract In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastroinTestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently Tested in the conditioned Defensive Burying Test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats (P,0·05) and alleviated psychological distress in volunteers, as measured particularly by the HSCL-90 scale (global severity index, P, 0·05; somatisation, P, 0·05; depression, P, 0·05; and anger-hostility, P,0·05), the HADS (HADS global score, P, 0·05; and HADSanxiety, P,0·06), and by the CCL (problem solving, P, 0·05) and the UFC level (P,0·05). L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers

  • Anxiolytic-like effects and safety profile of a tryptic hydrolysate from bovine alpha s1-casein in rats
    Fundamental and Clinical Pharmacology, 2009
    Co-Authors: Michael Messaoudi, Henri Schroeder, Robert Lalonde, Didier Desor
    Abstract:

    The anxiolytic activity and adverse benzodiazepine-like effects of a bovine alpha s1-casein tryptic hydrolysate (CH) were evaluated. The effects of CH orally administered at doses of 5 and 15 mg/kg were compared with those of diazepam (DZ) at 3 mg/kg in the conditioned Defensive Burying Test. Rats treated either with CH at 15 mg/kg or with DZ showed a decrease in anxiety. A drug-related difference was observed in terms of duration, as the anxiolytic-like action of CH was maintained after 7 days with twice-daily administration, whereas that of DZ was not. CH and DZ were then evaluated for their potential effects on memory in a passive avoidance paradigm. CH-treated rats had significantly longer latencies before entering the dark compartment where they were previously delivered a shock, indicating better retention relative to DZ-treated rats. In the final Test, CH and DZ were evaluated for place preference, an index of the possible addictive potential of these substances. DZ-treated rats spent more time in the compartment associated with drug exposure than control rats. This effect was not found in CH-treated rats. Thus, CH did not display side effects associated with DZ, despite its affinity for gamma-aminobutyric acid(A) (GABAA) receptors. Specific linking of CH on GABAA receptor function involved in anxiolysis, but not on that implied in memory-impairing effects, may be hypothesized to explain its specific activity. This profile might render it advantageous for nutritional purposes.

Nicolas Violle - One of the best experts on this subject based on the ideXlab platform.

  • assessment of psychotropic like properties of a probiotic formulation lactobacillus helveticus r0052 and bifidobacterium longum r0175 in rats and human subjects
    British Journal of Nutrition, 2011
    Co-Authors: Michael Messaoudi, Nicolas Violle, Didier Desor, Amine Nejdi, Robert Lalonde, Herve Javelot, Jeanfrancois Bisson, Catherine Rougeot, Matthieu Pichelin, Murielle Cazaubiel
    Abstract:

    In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastroinTestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently Tested in the conditioned Defensive Burying Test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats ( P P P P P P P P P L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers.

  • Assessment of psychotropiclike properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects
    2011
    Co-Authors: Michael Messaoudi, Nicolas Violle, Didier Desor, Amine Nejdi, Robert Lalonde, Herve Javelot, Jeanfrancois Bisson, Catherine Rougeot, Matthieu Pichelin, Murielle Cazaubiel
    Abstract:

    Abstract In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastroinTestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently Tested in the conditioned Defensive Burying Test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats (P,0·05) and alleviated psychological distress in volunteers, as measured particularly by the HSCL-90 scale (global severity index, P, 0·05; somatisation, P, 0·05; depression, P, 0·05; and anger-hostility, P,0·05), the HADS (HADS global score, P, 0·05; and HADSanxiety, P,0·06), and by the CCL (problem solving, P, 0·05) and the UFC level (P,0·05). L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers

  • ethological comparison of the effects of a bovine αs1 casein tryptic hydrolysate and diazepam on the behaviour of rats in two models of anxiety
    Pharmacology Biochemistry and Behavior, 2006
    Co-Authors: Nicolas Violle, Michael Messaoudi, Catherine Lefrancmillot, Didier Desor, Amine Nejdi, Benoit Demagny, Henri Schroeder
    Abstract:

    A bovine αS1-casein tryptic hydrolysate was previously demonstrated to display an anxiolytic-like activity in the conditioned Defensive Burying and in the elevated plus-maze models when i.p. injected. The present study assessed the anxiolytic-like effects of this tryptic hydrolysate after an oral administration in rats faced to the same behavioural situations using diazepam as a reference. In a first experiment, the behavioural effects of the hydrolysate in the conditioned Defensive Burying Test were investigated at doses ranging 5–50 mg/kg. The results showed that the minimal dose required to elicit an anxiolytic-like activity is 15 mg/kg. In a second experiment, the αS1-casein tryptic hydrolysate (15 mg/kg, p.o.) was demonstrated to display an anxiolytic-like activity similar to diazepam (3 mg/kg, p.o.) in the conditioned Defensive Burying Test and the elevated plus-maze. However, the ethological analysis of behaviour indicated that this hydrolysate has a different activity compared to diazepam. While diazepam induced a disinhibition state in rats, possibly related to the risk-taking behaviour observed after a benzodiazepine ingestion in humans, the tryptic hydrolysate did not display such a side effect. These results suggest that the mechanism of action of the bovine αs1-casein tryptic hydrolysate may differ from that of diazepam.

Defensive Burying Test - 15 days free trial to Access Experts & Abstracts